Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
By J. Toso, V. Gill, P. Hwu, F. Marincola, N. Restifo, D. Schwartzentruber, R. Sherry, S. Topalian, Jie Yang, F. Stock and 10 more. Journal of Clinical Oncology, 2002
762 citations recorded by the source corpus.
Subfields: Biotechnology, Food Science, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/a2e741e94b7fd7540a36249404502c72ec83ed9b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biotechnology
In Food Science
Citations in the corpus
- Exploiting tumour hypoxia in cancer treatment (2004, background): “, produced only marginal colonization of human tumours in a Phase I clinical tria”
- Microbiota in health and diseases (2022, background): “Such response was also observed in phase 1 clinical trial that administrated a modified Salmonella strain to patients with metastatic melanoma.(393) The second strategy is using engineered bacteria to directly express anticancer agents or transfer eukaryotic expression vectors into cancer cells.”
- Bio-inspired, bioengineered and biomimetic drug delivery carriers (2011, background): “Typhimurium is reduced or eliminated, and this system has demonstrated a good safety profile in Phase I studies in patients with cance”
- Engineering the perfect (bacterial) cancer therapy (2010, background): “This containment is one possible reason that attenuated Salmonella had limited success in reducing tumour growth in human trial”